REFERENCES

1. Xu F, Wu Q, Li L, Gong J, Huo R, Cui W. Icariside II: Anticancer Potential and Molecular Targets in Solid Cancers. Front Pharmacol. 2021;12:663776.

2. Daniel Y, Lelou E, Aninat C, Corlu A, Cabillic F. Interplay between metabolism reprogramming and epithelial-to-mesenchymal transition in cancer stem cells. Cancers. 2021;13:1973.

3. Dong S, Wu Y, Liu Y, Weng H, Huang H. N⁶ -methyladenosine steers RNA metabolism and regulation in cancer. Cancer Commun. 2021;41:538-59.

4. Zanotelli MR, Zhang J, Reinhart-King CA. Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 2021;33:1307-21.

5. Reina-Campos M, Scharping NE, Goldrath AW. CD8⁺ T cell metabolism in infection and cancer. Nat Rev Immunol. 2021;21:718-38.

6. Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J Clin. 2021;71:333-58.

7. Jin R, Hao J, Yi Y, Sauter E, Li B. Regulation of macrophage functions by FABP-mediated inflammatory and metabolic pathways. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866:158964.

8. Singh A, Anjum B, Naz Q, et al. Night shift-induced circadian disruption: links to initiation of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and risk of hepatic cancer. Hepatoma Res. 2024;10:46.

9. DeRosa A, Leftin A. The iron curtain: macrophages at the interface of systemic and microenvironmental iron metabolism and immune response in cancer. Front Immunol. 2021;12:614294.

10. Jia D, Park JH, Kaur H, et al. Towards decoding the coupled decision-making of metabolism and epithelial-to-mesenchymal transition in cancer. Br J Cancer. 2021;124:1902-11.

11. Sobanski T, Rose M, Suraweera A, O’Byrne K, Richard DJ, Bolderson E. Cell metabolism and DNA repair pathways: implications for cancer therapy. Front Cell Dev Biol. 2021;9:633305.

12. Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: new perspectives and emerging mechanisms. Dev Cell. 2021;56:1363-93.

13. Liu XZ, Pedersen L, Halberg N. Cellular mechanisms linking cancers to obesity. Cell Stress. 2021;5:55-72.

14. Moniri NH, Farah Q. Short-chain free-fatty acid G protein-coupled receptors in colon cancer. Biochem Pharmacol. 2021;186:114483.

15. Wang J, YangY , Lu J, Wang X. The role of exosomes in therapeutic resistance of hepatocellular carcinoma. Hepatoma Res. 2023;9:46.

16. Tucci S, Alatibi KI, Wehbe Z. Altered metabolic flexibility in inherited metabolic diseases of mitochondrial fatty acid metabolism. Int J Mol Sci. 2021;22:3799.

17. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537-64.

18. Nosrati-Oskouie M, Aghili-Moghaddam NS, Sathyapalan T, Sahebkar A. Impact of curcumin on fatty acid metabolism. Phytother Res. 2021;35:4748-62.

19. Laval T, Chaumont L, Demangel C. Not too fat to fight: the emerging role of macrophage fatty acid metabolism in immunity to Mycobacterium tuberculosis. Immunol Rev. 2021;301:84-97.

20. Nagarajan SR, Butler LM, Hoy AJ. The diversity and breadth of cancer cell fatty acid metabolism. Cancer Metab. 2021;9:2.

21. Tse EK, Salehi A, Clemenzi MN, Belsham DD. Role of the saturated fatty acid palmitate in the interconnected hypothalamic control of energy homeostasis and biological rhythms. Am J Physiol Endocrinol Metab. 2018;315:E133-40.

22. Cruz-Gil S, Fernández LP, Sánchez-Martínez R, Gómez de Cedrón M, Ramírez de Molina A. Non-coding and regulatory RNAs as epigenetic remodelers of fatty acid homeostasis in cancer. Cancers. 2020;12:2890.

23. Pfister E, Smith R, Lane MA. N-3 polyunsaturated fatty acid ethyl esters decrease the invasion, but not the proliferation, of human colorectal cancer cells via a PI3K-dependent mechanism in vitro. Prostaglandins Leukot Essent Fatty Acids. 2021;167:102273.

24. Luo X, Zheng E, Wei L, et al. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12:328.

25. Xu W, Lu Z, Wang X, et al. Gynura divaricata exerts hypoglycemic effects by regulating the PI3K/AKT signaling pathway and fatty acid metabolism signaling pathway. Nutr Diabetes. 2020;10:31.

26. Foerster F, Galle PR. The current landscape of clinical trials for systemic treatment of HCC. Cancers. 2021;13:1962.

27. Vogel A, Martinelli E; ESMO Guidelines Committee. Electronic address: [email protected], ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801-5.

28. Reig M, Cabibbo G. Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol. 2021;74:1225-33.

29. Zhong J, Kang Q, Cao Y, et al. BMP4 augments the survival of hepatocellular carcinoma (HCC) cells under hypoxia and hypoglycemia conditions by promoting the glycolysis pathway. Am J Cancer Res. 2021;11:793-811.

30. Li M, Shao J, Guo Z, et al. Novel mitochondrion-targeting copper(II) complex induces HK2 malfunction and inhibits glycolysis via Drp1-mediating mitophagy in HCC. J Cell Mol Med. 2020;24:3091-107.

31. Gao H, Hao Y, Zhou X, et al. Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncol Lett. 2020;19:691-9.

32. Yu Z, Wang D, Tang Y. PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma. Mol Cell Biochem. 2021;476:2001-10.

33. Liu M, Yu X, Lin L, et al. ATGL promotes the proliferation of hepatocellular carcinoma cells via the p-AKT signaling pathway. J Biochem Mol Toxicol. 2019;33:e22391.

34. Yao J, Man S, Dong H, Yang L, Ma L, Gao W. Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib. J Steroid Biochem Mol Biol. 2018;183:159-66.

35. Lally JSV, Ghoshal S, DePeralta DK, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174-82.e5.

36. Laha D, Grant R, Mishra P, Nilubol N. The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. Front Immunol. 2021;12:656908.

37. Ho WJ, Erbe R, Danilova L, et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol. 2021;22:154.

38. Crafa F, Vanella S, Imperatore V. Laparoscopic total mesorectal excision for low rectal cancer with unilateral partial autonomic nerve preservation - a video vignette. Colorectal Dis. 2021;23:2205-6.

39. Tanaka M, Masaki Y, Tanaka K, et al. Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep. 2013;7:365-70.

40. Heo CK, Woo MK, Yu DY, et al. Identification of autoantibody against fatty acid synthase in hepatocellular carcinoma mouse model and its application to diagnosis of HCC. Int J Oncol. 2010;36:1453-9.

41. Kim H, Lee DS, An TH, et al. Metabolic spectrum of liver failure in type 2 diabetes and obesity: from NAFLD to NASH to HCC. Int J Mol Sci. 2021;22:4495.

42. Longo M, Paolini E, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: the key switch from NAFLD/NASH to HCC. Int J Mol Sci. 2021;22:4173.

43. Myers S, Neyroud-Caspar I, Spahr L, et al. NAFLD and MAFLD as emerging causes of HCC: a populational study. JHEP Rep. 2021;3:100231.

44. Attal N, Sullivan MT, Girardi CA, Thompson KJ, McKillop IH. Fatty acid binding protein-4 promotes alcohol-dependent hepatosteatosis and hepatocellular carcinoma progression. Transl Oncol. 2021;14:100975.